Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review.

ABSTRACT:

Background and objective

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers. A major recent advance has been the identification of a subset of patients with PDAC who harbor inherited or somatic genetic alterations that result in homologous recombination deficiency (HRD) in tumor cells. These patients often respond favorably to drugs that can exploit this vulnerability. This review outlines the biomarkers that have been developed to predict HRD and their performance related specifically to PDAC, as well as novel HRD-targeted therapies for PDAC.

Methods

We conducted a narrative review of the HRD in PDAC based on PubMed, Google Scholar, website and citation searches.

Key content and findings

Germline mutations in BRCA1 and BRCA2

SUBMITTER: Tan H 

PROVIDER: S-EPMC10643583 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature